FDA approves Xarelto to prevent stroke in people with common type of abnormal heart rhythm
The U.S. Food and Drug Administration today approved the anti-clotting drug Xarelto (rivaroxaban) to reduce the risk of stroke in people who have abnormal heart rhythm (non-valvular atrial fibrillation).